JP2013521287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521287A5 JP2013521287A5 JP2012556123A JP2012556123A JP2013521287A5 JP 2013521287 A5 JP2013521287 A5 JP 2013521287A5 JP 2012556123 A JP2012556123 A JP 2012556123A JP 2012556123 A JP2012556123 A JP 2012556123A JP 2013521287 A5 JP2013521287 A5 JP 2013521287A5
- Authority
- JP
- Japan
- Prior art keywords
- imaging
- calcium channel
- type calcium
- channel inhibitor
- imaging marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003384 imaging method Methods 0.000 claims description 59
- 239000003550 marker Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 27
- 241000124008 Mammalia Species 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical group C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 claims description 7
- 229960004438 mibefradil Drugs 0.000 claims description 7
- 206010010904 Convulsion Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000002600 positron emission tomography Methods 0.000 claims description 4
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims description 3
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 3
- 230000018199 S phase Effects 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 238000002591 computed tomography Methods 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- FFEARJCKVFRZRR-JJZBXVGDSA-N methionine c-11 Chemical compound [11CH3]SCC[C@H](N)C(O)=O FFEARJCKVFRZRR-JJZBXVGDSA-N 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 229960005311 telbivudine Drugs 0.000 claims description 2
- DKNDOKIVCXTFHJ-HNNXBMFYSA-N 3,5-dichloro-n-[[1-[[(4s)-2,2-dimethyloxan-4-yl]methyl]-4-fluoropiperidin-4-yl]methyl]benzamide Chemical compound C1COC(C)(C)C[C@H]1CN1CCC(F)(CNC(=O)C=2C=C(Cl)C=C(Cl)C=2)CC1 DKNDOKIVCXTFHJ-HNNXBMFYSA-N 0.000 claims 31
- IJPVCOQVFLNLAP-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl fluoride Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(F)=O IJPVCOQVFLNLAP-SQOUGZDYSA-N 0.000 claims 2
- 230000006369 cell cycle progression Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 230000008051 G1/S transition checkpoint Effects 0.000 claims 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 11
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- -1 TTL-1177 Chemical compound 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30903010P | 2010-03-01 | 2010-03-01 | |
| US61/309,030 | 2010-03-01 | ||
| PCT/US2011/026416 WO2011109262A2 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013521287A JP2013521287A (ja) | 2013-06-10 |
| JP2013521287A5 true JP2013521287A5 (enExample) | 2014-07-31 |
| JP6017964B2 JP6017964B2 (ja) | 2016-11-02 |
Family
ID=44542787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556123A Expired - Fee Related JP6017964B2 (ja) | 2010-03-01 | 2011-02-28 | 癌診断および撮像 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9427429B2 (enExample) |
| EP (1) | EP2542155B1 (enExample) |
| JP (1) | JP6017964B2 (enExample) |
| KR (1) | KR101821343B1 (enExample) |
| CN (1) | CN102781316B (enExample) |
| AU (1) | AU2011223883B2 (enExample) |
| CA (1) | CA2787673A1 (enExample) |
| ES (1) | ES2557407T3 (enExample) |
| IL (1) | IL221035A0 (enExample) |
| MX (1) | MX360640B (enExample) |
| SG (2) | SG183114A1 (enExample) |
| WO (1) | WO2011109262A2 (enExample) |
| ZA (1) | ZA201205377B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2576191C (en) * | 2004-08-20 | 2013-03-19 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
| CN102781316B (zh) | 2010-03-01 | 2016-07-06 | 陶制药有限责任公司 | 癌症诊断和成像 |
| EP3487516A1 (en) * | 2016-07-19 | 2019-05-29 | Bristol-Myers Squibb Company | Radioligands for imaging the ido1 enzyme |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN110545806A (zh) | 2017-02-15 | 2019-12-06 | 卡维昂公司 | 钙通道抑制剂 |
| BR112021013766A2 (pt) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219609A (en) | 1968-07-19 | 1971-01-20 | Koninklijke Pharma Fab Nv | Diphenylmethoxyethylamino derivatives |
| US3732247A (en) | 1970-08-14 | 1973-05-08 | Robins Co Inc A H | 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms |
| US4091103A (en) | 1976-06-23 | 1978-05-23 | Ciba-Geigy Corporation | Quinolyl or isoquinolyl-lower-alkoxy-phenylene-amino derivatives |
| JPS59161392A (ja) | 1983-03-04 | 1984-09-12 | Nippon Shinyaku Co Ltd | ジヒドロピリジン誘導体及びその製法 |
| US4906646A (en) | 1983-03-31 | 1990-03-06 | Board Of Governors Of Wayne State University | Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class |
| US4885284A (en) | 1986-01-22 | 1989-12-05 | Nissan Chemical Industries Ltd. | Dihydropyridine-5-phosphonic acid cyclic propylene ester |
| FR2601366B1 (fr) | 1986-07-10 | 1988-11-25 | Andre Buzas | Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant. |
| DE68924456T2 (de) | 1988-08-02 | 1996-05-30 | Nissan Chemical Ind Ltd | Mittel zur Verbesserung von Arzneimitteleffekten für Antitumormittel. |
| JP2850376B2 (ja) | 1988-08-02 | 1999-01-27 | 日産化学工業株式会社 | 抗癌剤薬効増強剤 |
| FR2636946B1 (fr) | 1988-09-23 | 1990-11-02 | Lipha | ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0467435A3 (en) | 1990-07-19 | 1992-04-01 | Akzo N.V. | Benzhydryl derivatives having calmodulin inhibitor properties |
| GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
| US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US6413967B1 (en) | 1995-03-30 | 2002-07-02 | The University Of Virginia Patents Foundation | Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy |
| CA2228604A1 (en) | 1995-09-08 | 1997-03-13 | Jan E. Schnitzer | Isolation of microdomains of caveolae and gpi-anchored proteins |
| US5981539A (en) | 1995-09-15 | 1999-11-09 | Neurosearch A/S | Piperidine compounds as calcium channel blockers |
| DK0882061T3 (da) | 1996-02-14 | 2004-09-27 | Isis Pharmaceuticals Inc | Sukkermodificerede gapped oligonukleotider |
| CA2204082A1 (en) | 1996-05-03 | 1997-11-03 | Michael William John Urquhart | Pharmaceutical compounds |
| US6191156B1 (en) | 1997-04-11 | 2001-02-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating bladder dysfunction |
| US6703374B1 (en) | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
| EP1042468B1 (en) | 1997-12-03 | 2006-10-18 | Merck & Co., Inc. | Low-voltage activated calcium channel compositions and methods |
| EP1036170A1 (en) | 1997-12-05 | 2000-09-20 | Loyola University Of Chicago | T-type voltage-gated calcium channels and method of using same |
| US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| JPH11246417A (ja) | 1998-03-04 | 1999-09-14 | Nissan Chem Ind Ltd | 糖尿病性腎症治療用医薬組成物 |
| JP2002525077A (ja) | 1998-08-26 | 2002-08-13 | サウス、アラバマ、メディカル、サイエンス、ファウンデーション | Ｔ型カルシウムチャンネル |
| US6251886B1 (en) | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
| US6946475B1 (en) | 1999-04-07 | 2005-09-20 | University Of Virginia Patent Foundation | Anticancer calcium channel blockers |
| ATE269848T1 (de) | 1999-04-07 | 2004-07-15 | Univ Virginia | Calciumkanalblocker als antikrebsmittel |
| US7195783B2 (en) | 1999-07-09 | 2007-03-27 | Fx Life Sciences International Gmbh | Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics |
| WO2001062740A1 (en) | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Mibefradil analogues and their use |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| ATE357257T1 (de) | 2000-07-27 | 2007-04-15 | Pharmacia Corp | Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| WO2002092127A1 (en) * | 2001-05-11 | 2002-11-21 | Board Of Regents, The University Of Texas System | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
| JP2005501840A (ja) | 2001-07-23 | 2005-01-20 | エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト | 癌の改良された治療のための手段および方法 |
| WO2003062421A1 (en) | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| AU2003237863A1 (en) | 2002-05-20 | 2003-12-12 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
| GB0211578D0 (en) | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
| DE10227511A1 (de) | 2002-06-19 | 2004-01-08 | Max-Delbrück-Centrum für Molekulare Medizin | Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US20040127471A1 (en) | 2002-09-17 | 2004-07-01 | Barry Reisberg | Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors |
| RU2326886C2 (ru) | 2003-03-28 | 2008-06-20 | Ниссан Кемикал Индастриз, Лтд. | Блокатор кальциевых каналов т-типа |
| TW200528107A (en) | 2003-11-25 | 2005-09-01 | Nissan Chemical Ind Ltd | T-type calcium channel inhibitor |
| AU2011203315B8 (en) | 2004-02-11 | 2012-02-16 | University Of Virginia Patent Foundation | Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer |
| US20080160009A1 (en) | 2004-02-11 | 2008-07-03 | Gray Lloyd S | Inhibiting Cav3 Isoforms and the 25B Splice Varients for the Diagnosis and Treatment of Cancer |
| EP1730173A4 (en) | 2004-02-18 | 2008-10-08 | Merck & Co Inc | NUCLEIC ACID MOLECULES COORDINATING TO NEW MACHINE CALCIUM CHANNEL PROPERTIES ACTIVATED BY LOW VOLTAGES, DESCRIBED AS ALPHA 1H, PROCEDED PROTEINS, AND METHOD OF USE THEREOF |
| US20060003020A1 (en) | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
| TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| WO2006003020A1 (en) | 2004-07-02 | 2006-01-12 | L'oreal | Compositions containing a triazine derivative, an arylalkyl benzoate derivative and a eutectic n-butylphthalimide/isopropylphthalimide mixture; cosmetic uses thereof |
| US20100222406A1 (en) | 2007-09-11 | 2010-09-02 | University Of Virginia Patent Foundation | T Type Calcium Channel Blockers and the Treatment of Diseases |
| CA2576186A1 (en) | 2004-08-20 | 2006-03-02 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
| CA2576191C (en) | 2004-08-20 | 2013-03-19 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
| US20120264804A1 (en) | 2004-08-20 | 2012-10-18 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
| US7851431B2 (en) | 2005-07-27 | 2010-12-14 | Prescription Dispensing Laboratories | Treatment of actinic keratoses with calcium channel blockers |
| KR100743255B1 (ko) | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체 |
| CN101528768A (zh) * | 2006-08-10 | 2009-09-09 | 肿瘤疗法科学股份有限公司 | 与乳腺癌相关的基因和多肽 |
| JP5339291B2 (ja) * | 2006-08-10 | 2013-11-13 | オンコセラピー・サイエンス株式会社 | 乳癌に関連する遺伝子およびポリペプチド |
| US20080248033A1 (en) | 2006-12-19 | 2008-10-09 | Genentech, Inc. | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| US20100087398A1 (en) | 2007-05-02 | 2010-04-08 | Tau Therapeutics Llc | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| WO2008141189A1 (en) | 2007-05-09 | 2008-11-20 | Elixir Pharmaceuticals, Inc. | Ghrelin modulating compounds and combinations thereof |
| EP2190429B1 (en) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| JP5029328B2 (ja) | 2007-12-05 | 2012-09-19 | マツダ株式会社 | 自動車の前部車体構造 |
| US20110129456A1 (en) | 2008-05-05 | 2011-06-02 | Yaolin Wang | Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer |
| CN102112490B (zh) | 2008-07-08 | 2014-10-22 | 昂考梅德药品有限公司 | Notch1受体结合剂和其使用方法 |
| KR20120030112A (ko) | 2009-06-05 | 2012-03-27 | 타우 쎄라퓨틱스 엘엘씨 | 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법 |
| CN102781316B (zh) | 2010-03-01 | 2016-07-06 | 陶制药有限责任公司 | 癌症诊断和成像 |
| EP2755674A4 (en) | 2011-09-12 | 2015-04-08 | Tau Therapeutics Llc | ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS |
-
2011
- 2011-02-28 CN CN201180011495.2A patent/CN102781316B/zh not_active Expired - Fee Related
- 2011-02-28 SG SG2012055232A patent/SG183114A1/en unknown
- 2011-02-28 ES ES11751125.3T patent/ES2557407T3/es active Active
- 2011-02-28 JP JP2012556123A patent/JP6017964B2/ja not_active Expired - Fee Related
- 2011-02-28 MX MX2012010119A patent/MX360640B/es active IP Right Grant
- 2011-02-28 SG SG10201501496TA patent/SG10201501496TA/en unknown
- 2011-02-28 US US13/581,390 patent/US9427429B2/en not_active Expired - Fee Related
- 2011-02-28 AU AU2011223883A patent/AU2011223883B2/en not_active Ceased
- 2011-02-28 CA CA2787673A patent/CA2787673A1/en not_active Abandoned
- 2011-02-28 WO PCT/US2011/026416 patent/WO2011109262A2/en not_active Ceased
- 2011-02-28 EP EP11751125.3A patent/EP2542155B1/en not_active Not-in-force
- 2011-02-28 KR KR1020127022975A patent/KR101821343B1/ko not_active Expired - Fee Related
-
2012
- 2012-07-18 ZA ZA2012/05377A patent/ZA201205377B/en unknown
- 2012-07-19 IL IL221035A patent/IL221035A0/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bui-Nguyen et al. | A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial | |
| Haapaniemi et al. | Boron neutron capture therapy in the treatment of recurrent laryngeal cancer | |
| JP2013501731A5 (enExample) | ||
| JP6017964B2 (ja) | 癌診断および撮像 | |
| Wang et al. | BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua open-pool reactor | |
| JP2014528901A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2021522193A5 (enExample) | ||
| JP2016527202A5 (enExample) | ||
| Glinski et al. | Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: a phase I/II study | |
| JP6755457B2 (ja) | 合成アミノ酸の癌細胞内取り込みを保持する修飾法と正常細胞を保護する中性子捕捉療法 | |
| WO2012044783A8 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| JP2018502150A5 (enExample) | ||
| Altundag et al. | Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain | |
| Lan et al. | Prevention and early management of carotid blowout syndrome for patients receiving head and neck salvage boron neutron capture therapy (BNCT) | |
| RU2012122649A (ru) | Способ диагностики ишемии миокарда у больных кардиальным синдромом х | |
| RU2524309C1 (ru) | Способ выбора тактики лечения местно-распространенного рака предстательной железы | |
| RU2015152544A (ru) | Способы использования рифаксимина при сканированиях методом позитронной эмиссионной томографии (пэт) | |
| Wolffenbuttel et al. | Unexpected symptoms after rhTSH administration due to occult thyroid carcinoma metastasis | |
| US20220202804A1 (en) | Compositions and methods to treat cancer | |
| Nieder et al. | Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs? | |
| Sakurai et al. | Dose estimation for internal organs during boron neutron capture therapy for body-trunk tumors | |
| Cole | Decreasing time from decision to treat to radical radiotherapy in head and neck: development of a 14-day pathway | |
| Islam et al. | Marital status and survival in patients with multiple myeloma: The role of marriage in the management of multiple myeloma | |
| Damm | Hypertrophy induction of the left lobe of the liver after right hepatic yttrium-90 radioembolisation compared to portal vein embolisation |